Overview

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Status:
Completed
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
Phase:
Phase 1
Details
Lead Sponsor:
Shire
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions